ArticleCancer medicine2025
Association Between Immune-Related Adverse Events and Treatment Outcomes in Advanced Gastric Cancer Patients Receiving Nivolumab Plus Chemotherapy: A Retrospective Study.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Development and validation of a predictive model for high-risk immune-related adverse events in gastric cancer patients treated with ICIs.Human vaccines & immunotherapeutics · 2026Article
- Immune-Related Adverse Events of Cemiplimab Therapy in Advanced Cervical Cancer-Data from the Polish-Czech Cervical Cancer Immunotherapy Group (PCCIG-01) with a Review of the Literature.Antibodies (Basel, Switzerland) · 2026Article
- Review
- Association Between Immune-Related Adverse Events and Treatment Outcomes in Advanced Gastric Cancer Patients Receiving Nivolumab Plus Chemotherapy: A Retrospective Study.Cancer medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmune-related adverse events (irAEs) have been linked to improved outcomes in patients undergoing treatment with immune checkpoint inhibitors (ICIs) for various cancers. However, the relationship between irAEs and overall survival (OS) in patients with advanced gastric cancer (AGC) receiving chemoimmunotherapy remains unclear. This study aimed to explore the association between irAEs and treatment outcomes in patients with AGC receiving chemotherapy plus nivolumab.
methodsThis retrospective study analyzed clinical data from patients with HER2-negative AGC who received first-line chemotherapy (SOX, CapeOX, or FOLFOX) plus nivolumab at the National Cancer Center Hospital between November 2021 and February 2023. Patients were stratified into two groups based on the occurrence of irAEs. Outcomes, including OS and progression-free survival (PFS), were compared using Kaplan-Meier analysis, landmark analysis, and Cox proportional hazards regression.
resultsAmong the 60 patients analyzed, 15 (25%) developed irAEs of any grade, with 3 patients (5%) experiencing grade ≥ 3 irAEs. Patients with irAEs had significantly longer OS and PFS in comparison to those without irAEs (median OS: not reached vs. 17.1 months, p < 0.01; median PFS: not reached vs. 6.8 months, p < 0.01). Multivariate analysis identified the occurrence of irAEs as a favorable prognostic factor for OS (hazard ratio: 0.13; 95% CI: 0.03-0.59; p < 0.01).
conclusionThis study suggests that the occurrence of irAEs is associated with improved survival outcomes in patients with AGC receiving chemotherapy plus nivolumab. IrAEs may serve as a predictive marker for treatment response in this setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.